- Home
- OPP vs ANTX Comparison
OPP vs ANTX Comparison
Compare OPP & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$5.89
Company Overview
Basic Information| Metric | OPP | ANTX |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.4M | 172.9M |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | OPP | ANTX |
|---|---|---|
| Price | $7.45 | $5.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 88.6K | ★ 203.8K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.40 | $1.00 |
| 52 Week High | $8.77 | $7.19 |
Technical Indicators
Market Signals| Indicator | OPP | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.37 | 56.08 |
| Support Level | N/A | $3.91 |
| Resistance Level | $8.03 | $7.05 |
| Average True Range (ATR) | 0.08 | 0.35 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 12.50 | 56.79 |
Price Performance
Historical Comparison OPP
ANTX
About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.